Formic Ventures

Formic Ventures is a diversified venture capital firm that specializes in early-stage investments in biotechnology startups aimed at enhancing human longevity, alongside technology startups that strive to improve the quality of human life. Their mission is to empower individuals through valuable insights and in-depth understanding, leveraging technology to augment decision-making and combat the chaos that challenges humanity. By growing and organizing knowledge, they aim to expand understanding of the world and enhance productivity, performance, and longevity.

The firm's investment strategy focuses on biotechnology companies with the potential to expand human lifespan or accelerate the development of human progress in biotech. Additionally, they invest in AI, robotics, and other technology companies with exceptional founders who are impacting the future of humanity. Their portfolio includes companies like Insilico Medicine, an artificial intelligence platform for drug discovery and aging research; Schrodinger, a company revolutionizing drug discovery and materials design; Turn Bio, which is working on reversing aging by reprogramming cells; and Anduril, a firm developing cutting-edge AI software and hardware to solve complex national security challenges.

Formic Ventures is led by Michael Antonov, a software architect, investor, and serial entrepreneur passionate about taking on significant challenges that can make a difference in human lives, such as solving the problem of aging. Prior to founding Formic Ventures, Michael was the co-founder and Chief Software Architect at Oculus, which was acquired by Facebook. The team also includes Matt Shlosberg, Chief of Staff; Hayk Danielyan, Portfolio Manager; and Maria Konovalenko, Scientist in Residence, all bringing diverse expertise to the firm's mission of investing in human potential and advancing human longevity through technology and innovation.